Peginterferon alpha-2b biosimilar (Cadila Healthcare Limited)

N/A

Report date: 2025/03/07 17:34:54

Base Information

Drug NamePeginterferon alpha-2b biosimilar (Cadila Healthcare Limited)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMexico
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesZydus Lifesciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZydus Lifesciences Ltd
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A